QUCYNasdaqPharmaceutical PreparationsUS GAAP · USD

Quantum Cyber N.V.

Quantum Cyber N.V. is a U.S.-based life sciences company that has developed in-vitro diagnostic tests for early cancer detection, including colorectal and pancreatic screening products. The company has also held intellectual property and related assets tied to these diagnostic programs and has operated through subsidiaries and commercialization partners in Europe.

Ask about the company
Revenue0.5m USD
−39.9 %y/y
Operating profit (EBIT)-16.1m USD
+13.7 %y/y
EBIT margin-3,005.0%
−913.7 ppy/y
Net income-16.2m USD
+25.1 %y/y
Free cash flow-11.0m USD
+36.1 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-30-20-10010m USD20202021: 0.58 m USD2021: EBIT -9.7 m USD20212022: 0.53 m USD2022: EBIT -27 m USD20222023: 0.90 m USD2023: EBIT -27 m USD20232024: 0.89 m USD2024: EBIT -19 m USD20242025: 0.54 m USD2025: EBIT -16 m USD20250.54-16
RevenueOperating profit (EBIT)
Ask Clarifo about Quantum Cyber N.V.

Business

Share of revenue
Colorectal cancer screening55 %

Stool-based and related colorectal cancer detection products and assets.

Pancreatic cancer screening25 %

Blood-based and stool-based pancreatic cancer detection development programs.

Intellectual property and asset sales15 %

Sales of diagnostic IP, product assets, and related equipment or lease obligations.

Consumables and instrumentation5 %

Consumables and customer-located instruments used with diagnostic testing.

Customers

The company’s customers have included laboratory partners, diagnostic distributors, and other commercial counterparties involved in cancer screening workflows. Its products are designed for use in clinical testing settings where early detection, sample processing, and test commercialization matter. It also sells or transfers intellectual property and related assets to third-party buyers when monetizing product lines or programs.

Laboratory partners

Buy ColoAlert and related consumables for use in screening workflows and last-time purchases.

Diagnostic commercialization partners

Distribute or support cancer screening products in European markets.

IP and asset buyers

Acquire product lines, intellectual property, and related equipment for strategic use.

Clinical testing end users

Use the company’s diagnostic products through partner channels for early cancer detection.

Future strategic collaborators

Potential partners for development and commercialization of pancreatic screening programs.

Strategy

The company’s strategy has centered on narrowing its focus to pancreatic cancer screening while monetizing legacy colorectal assets. It has also signaled an expanded emphasis on post-quantum cybersecurity alongside continued pursuit of blood-based pancreatic cancer detection, making the business a hybrid of life sciences and adjacent technology ambitions. Capital raising and strategic partnerships remain important to fund development and commercialization efforts.

Advance pancreatic cancer screening commercializationMedium term

This is the remaining core life sciences program after the colorectal exit.

Monetize non-core diagnostic assetsShort term

Asset sales can convert legacy IP into cash and simplify the portfolio.

Secure external financingShort term

Development-stage diagnostics require ongoing capital for R&D and operations.

Geography

The company has historically operated in Europe through its German subsidiary and marketed ColoAlert in European markets. Its development and commercialization efforts have also been oriented toward the United States and Europe, while recent asset sales included a buyer incorporated in Italy. Geography matters because the business depends on cross-border regulatory, partner, and commercialization pathways.

Risks

The company faces going-concern and financing risk because it has recurring losses and depends on external capital to fund development and operations. It also faces execution risk in diagnostic development, regulatory approval, and commercialization, especially as it transitions away from its legacy colorectal business. Additional risk comes from asset divestitures, partner dependence, and the uncertainty of building a new strategic identity around pancreatic screening and cybersecurity.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Going-concern and liquidity dependence1Commercialization and regulatory risk2Portfolio transition risk3Partner concentration and asset monetization risk4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Going-concern and liquidity dependenceImpact: CriticalLikelihood: Medium

    The company has recurring losses and needs external financing to continue operations.

    ExposureR&DRegulatoryCommercial programs
  2. Commercialization and regulatory riskImpact: HighLikelihood: Low

    Diagnostic products require validation, approvals, and market adoption before scaling.

    Exposure: Pancreatic screening and any future launches

  3. Portfolio transition riskImpact: HighLikelihood: Low

    Exiting colorectal cancer screening can reduce near-term revenue and operational continuity.

    Exposure: Legacy product lines and partner relationships

  4. Partner concentration and asset monetization riskImpact: MediumLikelihood: Low

    Revenue and cash generation depend on a limited set of lab partners and buyers.

    Exposure: ColoAlert sales and IP transactions

Ask Clarifo about Quantum Cyber N.V.

Accounting

Judgemental items
Revenue recognition for diagnostic product sales

Sales may include product shipments and last-time buys, affecting quarter-to-quarter comparability.

Impact: Reported revenue and gross margin

Discontinued operations

The colorectal business is presented separately after the exit decision, changing trend analysis.

Impact: Operating income and revenue comparability

Impairment of fixed and intangible assets

Asset sales and business exits can trigger write-downs of related assets.

Impact: Operating expenses and asset values

Stock-based compensation

Equity awards can materially affect G&A expense in a development-stage company.

Impact: General and administrative expense

Similar listed companies

Publicly listed companies with a comparable business focus.

Quantum Computing Inc.

QUBT · Services-Prepackaged Software

Q/C Technologies, Inc

QCLS · In Vitro & In Vivo Diagnostic Substances

Quarta-Rad, Inc.

QURT · Industrial Instruments For Measurement, Display, and Control

Qiagen N.V

QGEN · Biological Products, (No Diagnostic Substances)

Quanterix Corp

QTRX · Laboratory Analytical Instruments

Guardant Health, Inc.

GH · Services-Medical Laboratories

Last updated: 24/09/2026